JD Health Launches 'Nurse-to-Home' Service Amid Pharma Rep Crackdown Over Speaker Fees
JD Health
Internet Medical and Health Service Platform Provider
Ribo Life Science
Small Nucleic Acid Drug Developer
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
Drug representatives have become a high-risk profession.
Recently, according to reports from multiple industry public accounts, in Hubei Province, two regional managers and two pharmaceutical representatives from three pharmaceutical companies have been subjected to criminal coercive measures. All of them were suspected of bribery towards non-government employees through lecture fees and academic conferences.
Enjoy Medical Services at Home.
Currently, JD Health has launched the "Nurse to Home" service, with 27 nursing service items now online, covering 14 cities in China including Beijing, Shanghai, Guangzhou, and Shenzhen. It is expected to cover 50 cities by the end of this year. So, would you use this service?
Beijing Transplant of "Artificial Heart" Included in Medical Insurance
On September 24, the Beijing Municipal Medical Insurance Bureau recently issued a notice that the installation of implantable left ventricular assist pumps, left ventricular assist pumps, and catheter fixation devices have been included in the Class A reimbursement scope of Beijing's medical insurance. Transplantation of "artificial hearts" at four hospitals—Beijing Anzhen Hospital, Fuwai Hospital of the Chinese Academy of Medical Sciences, Beijing Chaoyang Hospital, and Peking University Third Hospital—can be reimbursed by medical insurance.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Beijing Transplant "Artificial Heart" Included in Medical Insurance
On September 24, the Beijing Municipal Medical Insurance Bureau recently issued a notice stating that the installation surgery of implantable left ventricular assist pumps, left ventricular assist pumps, and catheter fixation devices have been included in the Class A reimbursement scope of Beijing's medical insurance. The transplantation of "artificial hearts" at four hospitals—Beijing Anzhen Hospital, Fuwai Hospital of the Chinese Academy of Medical Sciences, Beijing Chaoyang Hospital, and Peking University Third Hospital—can be reimbursed by medical insurance.
2) Multiple pharmaceutical companies' drug representatives arrested due to lecture fees
Recently, according to reports from multiple industry public accounts, in Hubei Province, two regional managers and two pharmaceutical representatives from three pharmaceutical companies have been subjected to criminal coercive measures. All of them were suspected of bribery towards non-government employees through lecture fees and academic conferences.
3) Chairman of Shiyao Innovation Pharmaceutical Resigns
On September 23, Stone Pharma Innovation, also known as Xinyu Pharma, announced that the board of directors had received written resignation reports from Chairman Weidong Pan and company director Dong Yang.
4) Ribo Life Science and PHEIRON Reach Strategic Cooperation on AI-Assisted RNA Drug Development
Recently, Ribo Life Science and its subsidiary Ribocure announced a strategic partnership with PHEIRON to accelerate the R&D of RNA drugs by leveraging PHEIRON's advanced AI platform, PheironGPS.
/ 02 /
Capital Information
1) SSE Terminates the Review of Shangkang Pharmaceutical's STAR Market IPO
On September 24, Shenzhen Shanyue Pharmaceutical and its sponsor, Guotai Securities, withdrew their application for issuance and listing. The Shanghai Stock Exchange terminated the review of its STAR Market issuance and listing.
/ 03 /
Pharmaceutical News
1) SDTM001 Injection from Saide Special Bio Obtains Clinical Approval
On September 24, according to the CDE website, Sadat Biotech's SDTM001 Injection received clinical approval for use in NSCLC patients with EGFR mutation-negative and PD-L1 expression-negative status following radical surgery.
2) Fosun Yalifeng Freeze-Dried Human Rabies Vaccine (Human Diploid Cells) Receives Clinical Approval
On September 24, according to the CDE official website, Fosun Yalifeng's freeze-dried human rabies vaccine (human diploid cells) received clinical approval and is intended for the prevention of rabies.
3) Yunda Shuyang Subcutaneous Injection Human Immunoglobulin Receives Clinical Approval
On September 24, according to the CDE official website, Yuanda Shuyang's subcutaneous injection of human immunoglobulin obtained clinical approval and is planned to be studied for the treatment of primary immunodeficiency diseases.
4) Boan Pharmaceutical HKG-215 Receives Clinical Approval
On September 24, according to the CDE official website, Boan Pharmaceutical's HKG-215 received clinical approval and is intended for the treatment of digestive system diseases caused by excessive gastric acid secretion.
5) Ribo Life Science's Zebetumab Injection Receives Clinical Approval
On September 24, according to the CDE official website, Ribo Life Science's Zebeto Monoclonal Antibody Injection received clinical approval for the intended treatment of primary membranous nephropathy.
6) Novartis Lutetium [177Lu] Texiveptide Injection Granted Priority Review
On September 24, according to the CDE website, Novartis’ Lutetium [177Lu] Texiveptide Injection is proposed for priority review. It is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) that is positive for prostate-specific membrane antigen (PSMA), and who have received androgen receptor pathway inhibitors and taxane chemotherapy.
7) Baili Pharmaceuticals' Injectable BL-B01D1 Granted Breakthrough Therapy Designation
On September 23, according to the CDE official website, Baili Pharmaceutical's injectable BL-B01D1 is proposed to receive breakthrough therapy designation for patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer who have previously failed treatment with anti-PD-1/PD-L1 monoclonal antibodies and platinum-based chemotherapy.
/ 04 /
Instrument Tracking
1) WisMedical Obtains Medical Device Registration Certificate for Nd:YAG Frequency-Doubled Picosecond Laser Therapy Device
On September 24, WisMedical announced that the company recently received a Medical Device Registration Certificate issued by the National Medical Products Administration. The product name is Nd:YAG Frequency-Doubled Picosecond Laser Therapy Device. This product is intended for use in medical institutions to treat epidermal benign hyperpigmentation skin diseases.
2) Huadong Medicine's Intense Pulsed Light and Radiofrequency Therapy Device V20 Approved for Marketing
On September 24, Huadong Medicine announced that Viora, its wholly-owned subsidiary, received approval for the listing of its V20 intense pulsed light and radiofrequency therapy device.
/ 05 /
Digital Healthcare Daily
1) JD Health Launches "Nurse to Home" Service
JD Health Launches "Nurse to Home" Service, Now Offering 27 Nursing Service Items, Covering 14 Cities in China Including Beijing, Shanghai, Guangzhou, and Shenzhen, with an Expected Expansion to 50 Cities by the End of This Year.
/ 06 /
Overseas Pharmaceutical News
1) Otsuka Pharmaceutical Completes Acquisition of Autoimmune Drug Company
On September 24, Otsuka Pharmaceutical announced that it had completed the previously announced acquisition agreement with autoimmune drug company Jnana Therapeutics.
2) Astellas' CLDN18.2 Monoclonal Antibody Approved for Marketing in South Korea
On September 23, Astellas Korea announced that the South Korean Ministry of Food and Drug Safety had approved CLDN18.2 monoclonal antibody Vyloy (zolbetuximab) for the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.
